argenx SE (ARGX)
| Market Cap | 50.25B +46.2% |
| Revenue (ttm) | 4.74B +79.4% |
| Net Income | 1.49B +39.9% |
| EPS | 22.49 +41.1% |
| Shares Out | 62.06M |
| PE Ratio | 33.75 |
| Forward PE | 26.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 359,241 |
| Open | 823.68 |
| Previous Close | 836.09 |
| Day's Range | 799.68 - 823.68 |
| 52-Week Range | 510.06 - 934.62 |
| Beta | -0.06 |
| Analysts | Buy |
| Price Target | 1,029.94 (+28.39%) |
| Earnings Date | May 7, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,029.94, which is an increase of 28.39% from the latest price.
News
Argenx price target raised to $1,291 from $1,260 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,291 from $1,260 and keeps an Overweight rating on the shares. The firm remains constructive into Vyvgart’s Phase 3…
Argenx price target raised to $1,255 from $1,222 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Argenx (ARGX) to $1,255 from $1,222 and keeps a Buy rating on the shares. Phase 3 data for the ALKIVIA…
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
Argenx price target raised to $1,059 from $1,007 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx (ARGX) to $1,059 from $1,007 and keeps an Outperform rating on the shares.
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty dominate the policy landscape, with drug pricing reforms and MFN agreements creating long-term industry vulnerabilities. China’s rise in biopharma is accelerating, prompting bipartisan concern but limited immediate legislative action. Expect regulatory focus and oversight to increase post-election, with major reforms unlikely this year.
Argenx price target raised to $1,016 from $1,013 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo…
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biolog...
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,135 from $1,120 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,135 from $1,120 and keeps a Buy rating on the shares. The firm adjusted estimates following the…
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with…
Argenx price target lowered to $1,222 from $1,227 at Stifel
Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management…
argenx SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 63% revenue growth to $1.3B, strong operating leverage, and expanding VYVGART adoption in MG and CIDP. Pipeline progress and label expansions are set to drive further growth, with robust cash reserves supporting continued investment.
argenx SE Earnings release: Q1 2026
argenx SE released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
argenx SE Slides: Q1 2026
argenx SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of peo...
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an...
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
argenx (ARGX) announced the presentation of new data for Vyvgart in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy at the 2026 American Academy of Neurology, AAN, Annual Meeti...
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O...
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered the firm’s price target on Argenx (ARGX) to $1,014 from $1,060 and keeps an Outperform rating on the shares. The firm made a variety of…
Argenx added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Argenx (ARGX) to the firm’s European Conviction List as part of its monthly update. Goldman views current share levels as a “compelling entry point into a…
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the...
Argenx upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx (ARGX) to Buy from Hold with a price target of EUR 725, up from EUR 675.
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
As previously reported, Deutsche Bank upgraded Argenx (ARGX) to Buy from Hold with a price target of EUR 725, up from EUR 675. Despite a “somewhat underwhelming” Q4 report on…